SEATTLE, Sept. 4 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. announced today that Dr. Peter Thompson, president, chief executive officer, and chairman of Trubion, will present an overview of the company at three September investor conferences:
-- BioCentury’s NewsMakers in the Biotech Industry conference at the
Millennium Broadway Hotel & Conference Center, 145 W. 44th St., New
York. Dr. Thompson is scheduled to present on Thursday, Sept. 6. A
webcast of the presentation will be available at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=TRBN&item_id=1630470.
-- Bank of America 37th Annual Investment Conference at the Ritz-Carlton, 600 Stockton St. (at California St.), San Francisco. Dr. Thompson is scheduled to present on Monday, Sept. 17. A webcast of the presentation will be available at http://www.veracast.com/webcasts/bas/37th-annual-2007/id22113469.cfm. -- UBS Global Life Sciences Investor Conference at the Grand Hyatt, 109 E. 42nd St. (at Grand Central Station), New York. Dr. Thompson is scheduled to present on Monday, Sept. 24. A webcast of the presentation will be available at http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924.
About Trubion
Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company’s product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months the Company designed, developed and submitted to the FDA an Investigational New Drug application for, its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion’s TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit http://www.trubion.com.
Trubion Pharmaceuticals, Inc.
CONTACT: Jim DeNike, Senior Director, Corporate Communication of TrubionPharmaceuticals, Inc., +1-206-838-0500, jdenike@trubion.com; or JennyMoede, Senior Vice President of Waggener Edstrom Healthcare,+1-503-443-7000, jmoede@wagged.com for Trubion Pharmaceuticals, Inc.
Web site: http://www.trubion.com/
